Skye Bioscience Inc (SKYE)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.04-8.77%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · SKYE
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance dropped from the top half to the bottom half of its industry over the past month — the reason to own it has weakened.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
SKYE — M&A activity — Termination of a Material Definitive Agreement
Dated 2026-09-11
Termination of a Material Definitive Agreement. On September 8, 2026, in connection with the resignation of John P. Sharp as Chief Financial Officer and principal financial and accounting officer of Skye Bioscience, Inc., a Nevada corporation (the “Company”), the Company provided written notice to Lohman & Associates, Inc. of its intent to terminate the Master Services Agreement, dated March 31, 2026, by and between the Company and Lohman & Associates, Inc. (the “Master Services Agreement”),…
Why it matters: The announced funds are meant to carry Fibrx through key clinical steps. A shortfall could weaken that plan.
Supportive ifDeal filings confirm about $125 million in gross proceeds from planned financings. This includes the $68 million PIPE and $36 million Series A.
Worry ifThe financings close below about $125 million, or a named part is canceled or delayed.
Why it matters: RXC008 is the lead drug for the new company. Its Phase 2 study is the next key test before topline data in H2 2028.
Supportive ifFibrx reports that the RXC008 Phase 2 study has begun and keeps H2 2028 as its topline data window.
Worry ifFibrx reports a delay to the study start or moves the H2 2028 topline window later.
Why it matters: An IND filing would move a second fibrosis program toward human testing. A delay would leave RXC008 as the main clinical program.
Supportive ifFibrx files an IND for a DDR inhibitor with the FDA during 2027.
Worry ifFibrx states that the DDR IND filing has slipped beyond 2027, or drops the program before filing.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$313 on $10,000 · ±3.1% | How much price usually moves either way. |
| Bad day | $879 loss on $10,000 · 8.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,069 loss on $10,000 · 90.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.